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a  b  s t r a  c t
Bovine  serum albumin-piroxicam  (BSA-piroxicam)  and human  serum albumin-piroxicam (HSA-
piroxicam)  microspheres  were  sonochemically  prepared  and  characterized.  The use of polyvinyl  alcohol
(PVA)  lead  to an  improvement  of formulation  characteristics,  including  smaller size,  lower  polydis-
persity  index  (PDl),  higher entrapment efficiency  and higher  stability. The  release kinetics of these
proteinaceous  microspheres  was  determined  in  presence  of protease,  indicating  an anomalous  drug
transport  mechanism  (diffusion and polymer  degradation).  In  presence of higher  protease  concentra-
tion,  BSA microspheres  exhibit Case  II  transport, leading  to zero  order  release (protein  degradation).
These  proteinaceous devices did  not  show  cytotoxicity  against  human  skin  fibroblasts  in  vitro,  for range
concentrations  below  to 300 mg L−1,  greatly supporting  their  potential  application in the  treatment of
inflammatory  diseases.
© 2011 Elsevier B.V. All rights reserved.
1. Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are  the most
widely used drugs in  the treatment of  inflammatory diseases, such
as rheumatic disease, but are  also being increasingly used for non-
rheumatic conditions, including acute and chronic pain, biliary
and ureteric colic, dysmenorrheal inflammation and fever [1].  The
mechanism of action of  NSAIDs is  mediated by  its  capacity to inhibit
cyclo-oxygenase (COX) activity. The COX enzyme can be divided
into two isoforms – a constitutive isoform (COX-1), which is respon-
sible for maintaining normal function in the gastrointestinal and
renal tracts, for example, and an  inducible isoform (COX-2), which is
found in areas of inflammation and in the brain [2]. It  has  been sug-
gested that the anti-inflammatory actions of  NSAIDs are  due to the
inhibition of  COX-2, whereas the unwanted side-effects are due to
the inhibition of COX-1 [3–5]. The vast majority of  NSAIDs currently
available is not selective for COX-2 and can thus cause the adverse
reactions so commonly seen during NSAIDs treatment [3–5]. There-
fore, the entrapment in microspheres of the NSAIDs, such as
piroxicam, which are not selectively targeting COX-2, could be
useful to minimize their  adverse reactions. Various types of macro-
molecular substances, such as synthetic and natural polymers have
been used in drug delivery research, as they can effectively deliver
the drug to target the action site and thus increasing the thera-
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peutic benefit, while minimizing the side effects [6–10]. Recently,
protein microspheres have been shown efficacy as biodegradable
and biocompatible carrier, which can incorporate a variety of  drugs
in relatively non-specific fashion [11–15].  Albumin is a  promising
material and has  been extensively investigated as drug  delivery
system, because of its biodegradability and low toxicity [16,17].
In addition, albumin proteins has a functionality for transport-
ing different macromolecules in the bloodstream to target organs
making it  a  potential macromolecular carrier for the site-directed
delivery of drugs [18]. Four of the most important characteristics
of particles are their size (presence of low polydispersity, bellow
0.1), entrapment efficiency, zeta-potential (surface charge), and
the release characteristics [19]. Previous studies demonstrate that
3 min  of sonication promote the entrapment of  different compo-
nents, such as antibiotic (tetracycline) [20], anti-cancer drugs (taxol
and gemcitabine) [11,12] or even RNA molecules [21]  in bovine
serum albumin (BSA) microspheres with approximately 2  mm of
diameter with a high polydispersity index. However, the profile
as well as the mechanism for the release of  bioactive components
at the targeted environment is  not clarified. The main aim of  this
research was  to study the efficiency of  the sonochemical method for
the entrapment of piroxicam in protein microspheres, using bovine
or human serum albumin (HSA) as starting material, and to study
the possibility of using the proteinaceous devices as a  drug-delivery
agent, determining their release kinetics in the presence of pro-
tease. Moreover, further miniaturization of the microspheres, to
improve their colloidal stability and the entrapment efficiency of
drug, was  also performed via different stabilizers: polyvinyl alco-
hol  (PVA), pluronic acid F68 (pluronic F68) and tween 80. Herein,
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this approach was applied in  order to obtain particles with small
diameters and a  monodisperse population (polydispersity index
lower than 0.1) increasing their surface area promoting at the same
time a faster drug released. The ability of  proteins to form micro-
spheres was evaluated by quantifying protein concentration with
the Lowry assay on the supernatant after ultrasound treatment [22].
Particle size, as well as the polydispersity index (PDl), of micro-
spheres, was evaluated by  photon correlation spectroscopy (PCS).
It is well known that the particle size can significantly affect the
microspheres properties and is important for their interaction with
the biological environment [23].  Particle size  values are  thus cru-
cial in the development and optimization of  preparation process.
In addition the zeta-potential of microspheres was also evaluated
by  electrophoretic laser Doppler anemometry, to obtain an indi-
cation of surface potential. The scanning transmission electron
microscopy (STEM) has been employed to characterize the overall
structure and shape of the microspheres. The entrapment efficiency
of piroxicam in  microspheres was assessed and the release profile
was evaluated in the presence of a  protease. Finally, microspheres
were screened for cytotoxicity using a metabolic assay on an  human
fibroblast cell line.
2. Materials and methods
2.1. Materials
The anti-inflammatory drug, piroxicam, was acquired from
Sigma (Spain), as well as  the PVA (Mw = 30.000–70.000 Da, and
87–90% hydrolyzed), tween 80 and pluronic F68. The BJ5ta cell
line (telomerase-immortalized human normal skin fibroblasts)
was purchased from the European Collection of Cell Cultures
(ECACC) and cultured according to  ATCC recommendations. The
centricon tubes (molecular-weight cut-off of  100  kDa, Amicon)
were purchased from Amicon. All other reagents, including those
used in the cell culture, were analytical grade and purchased from
Sigma (Spain).
2.2. Equipment
The experimental set  up used was composed of a probe  type
ultrasound source (20 kHz Sonics & Materials Vibracell CV 33) fitted
with a 3 mm diameter titanium micro-tip. Power delivery was  con-
trolled as percentage amplitude. The reaction vessel was an open
glass cell (diameter 19 mm  and height 75  mm),  which contained
16 mL  of  sample solution. The sonochemical reactor temperature
was controlled via a thermo-stated water bath with a freezer
exchanger placed within a thermo jacket cell; this gave a  steady
operating temperature of 10 ± 1 ◦C. Temperature was monitored
throughout using K  type thermocouples (TC).
2.3. Sonochemical preparation of proteinaceous microspheres
Microspheres, with or without anti-inflammatory drug, were
synthesized by  an adaptation of the Suslick and Grinstaff method
[24]. The piroxicam (3 mM)  was added to protein solution (5 g L−1)
and layered with vegetable oil. The very low solubility of piroxicam
required the use of dimethyl sulfoxide:water solutions (1:99 v/v).
When surfactants were  used as  stabilizer, they were dissolved in
aqueous phase. The  bottom of  the high-intensity ultrasonic horn
was  positioned at the aqueous/organic interface employing an
amplitude of 40% with a  temperature of 10 ± 1 ◦C  and with a total
treatment of 3  min. The separation of phases was accomplished
in a few minutes, due to the lower density of  microspheres, rel-
ative to the density of water. After, microspheres were collected by
centrifugation (2000 × g,  30  min) using the centricon tubes. Finally,
the microspheres were sterilized with UV radiation over  2 h.
2.4. Determination of microspheres yield
The efficiency of microspheres formation was performed via
Lowry method [22],  using BSA  as standard. This method was  based
on the determination of  protein in the supernatant. The efficiency
of microspheres formation was calculated as follows:
Microspheres formation (%) =
[Protein]total −  [Protein]supernatant
[Protein]total
× 100
(1)
where [Protein]total and [Protein]supernatant is  the initial and the
final protein concentration in the aqueous solution, respectively.
2.5. Determination of size and zeta-potential
The zeta-potential and the size distribution of  microspheres
were determined at 25.0 ± 0.1 ◦C using a Malvern zetasizer NS
(Malvern Instruments) by electrophoretic laser Doppler anemom-
etry and photon correlation spectroscopy (PCS), respectively. The
proteinaceous microspheres were diluted 1:100, and in  order to
verify the reproducibility of  the proteinaceous microspheres prepa-
ration assembled under the typical process described above, the
procedure was carried out at least three times for each of the
individual microspheres. The results were  expressed as mean
value ±  standard deviation.
2.6. Scanning transmission electron microscopy (STEM)
For  STEM analysis, the diluted microspheres suspension was
dropped in Copper grids with carbon film 400  meshes, 3  mm diam-
eter. The shape and morphology of  microspheres were observed
using a NOVA Nano SEM 200  FEI.
2.7. Entrapment efficiency of piroxicam
Entrapment efficiency of  piroxicam in proteinaceous micro-
spheres was measured by UV spectrophotometry, at 353 nm using a
Helios g ThermoSpectronic spectrophotometer (Unicam). The sep-
aration of free piroxicam was  achieved by centrifugation of samples
at 2000 × g for 30  min, using  the centricon tubes (molecular-weight
cut-off of  3 kDa). The entrapment efficiency of piroxicam was deter-
mined as follow:
Entrapment (%) =
[Piroxicam]initial − [Piroxicam]final
[Piroxicam]final
×  100 (2)
where [Piroxicam]initial is the initial concentration of piroxicam
used and [Piroxicam]final is the final concentration of  piroxicam
in supernatant. Measurements were recorded in triplicate and the
results were expressed as mean value ± standard deviation.
2.8. In vitro piroxicam release profile from proteinaceous
microspheres
The enzymatic degradation of the developed carrier systems
was investigated by incubating the microspheres in  phosphate
buffered saline solution (PBS, 0.01 M, pH = 7.4)  with different con-
centrations of  protease, subtilisin from Bacillus sp.  (E.C. 3.4.21.62),
(0.075, 0.50 and 3.0 U mL−1). The selected enzyme was used to
mimicking the enzymatic environment of the human body and as a
trigger for drug release. The microspheres were incubated at room
temperature under constant shacking (50–60 rpm). At determined
time points, aliquots were taken and the piroxicam release was
monitored by absorbance measurements at wavelength of 353 nm
using a Helios  g ThermoSpectronic spectrophotometer (Unicam).
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The quantification of the release was  established by a standard
absorbance curve. All the release experiments were carried out in
triplicate and for  a  period of 6 days. Results are  reported as aver-
age ± standard deviation.
2.9. Drug release kinetics
The release behavior of compounds from polymeric systems can
be determined by fitting the release data to the empirical relation-
ship given by the Ritger–Peppas equation:
Mt
M∞
= ktn (3)
where Mt/M∞ is  the fractional drug release at time t;  t  is the release
time; k is the kinetic constant, and n is the diffusion exponent
characteristic of  the release mechanism. To determine n values for
proteinaceous microspheres, Eq.  (3) is transformed in Eq. (4),  and
n is determined from the slope of  the plot of  log (%  release) versus
log t.
log (%released) = log
(
Mt
M∞
)
= log k  + n log t (4)
2.10. Cytotoxicity evaluation
The cytotoxicity of BSA and HSA  microspheres, containing pirox-
icam, was evaluated using murine embryonic fibroblasts cells
(MEFs), isolated from E13.5 embryos and normal human skin
fibroblasts (BJ5ta), from American type culture collection (ATCC).
The BJ5ta cell line (normal human skin fibroblasts) was maintained
according to ATCC recommendations (4 parts Dulbecco’s modified
Eagle’s medium (DMEM) containing 4 mM l-glutamine, 4.5 g L−1
glucose, 1.5 g L−1 sodium bicarbonate and 1 part  of Medium 199,
supplemented with 10% (v/v) of fetal bovine serum (FBS), 1% (v/v)
of Penicillin/Streptomycin solution and 10 mg  mL−1 hygromycin B).
The cells were maintained at 37 ◦C in a  humidified atmosphere
of 5% CO2. Culture medium was  refreshed every 2–3  days. Cells
were seeded at a density of  10 × 103 cells/100 mL/well on 96-well
tissue culture polystyrene (TCPS) plates (TPP, Switzerland), in the
day before of  experiments, and then  exposed to  different micro-
spheres concentrations, as well as to different controls solutions
(BSA and HSA solutions, vegetable oil; PVA solution; piroxicam
solution) added to  fresh culture medium. At 24, 48 and 72  h of  expo-
sure, cell viability was determined using the alamarBlue® assay
(Invitrogen, EUA). 10 mL of  alamarBlue compound was  added to
each well containing 100  mL  of culture medium. After 4 h of incuba-
tion at 37 ◦C the absorbance at 570  nm,  using 600 nm as a reference
wavelength, was measured in a microplate reader (Spectramax
340PC). The quantity of resorufin formed is directly proportional
to the number of viable cells. Data are  expressed as means
with standard errors of the means. Two-way ANOVA followed by
post hoc Bonferroni test (GraphPad Prism 5.0 for Windows) was
employed with statistically significant differences when P  < 0.05.
The samples were tested at least in  triplicates per two  independent
experiments.
3. Results
3.1. Influence of stabilizer addition in microspheres
characterization parameters
In  this work, matrices based on BSA or HSA  proteins, were pro-
duced and characterized. To ensure microspheres suitability for the
intended type of  application and to enable a  focused development
of dispersions with specific properties, the characteristics of  the
dispersions have to be known in detail.
Table 1
Effect of PVA on Z-average (nm), PDI  and zeta-potential (mV)  values of BSA
microspheres.
PVA amount (%) Z-Average (nm) PDl Zeta-potential (mV)
0 402.9 ± 65.1 0.44  ± 0.03 −15.6 ±  1.5
2 392.7  ± 20.1  0.35  ± 0.01 −4.7 ±  0.3
4 378.1  ± 40.6  0.18  ± 0.08 −3.9 ±  0.6
6 340.4 ± 15.6 0.15  ± 0.06 −3.8 ±  0.2
8 257.9  ± 5.90  0.06 ± 0.04 −3.9 ±  0.1
10  259.1  ± 4.20  0.06 ± 0.06 −3.7 ±  0.3
Values reported are the mean  ± SD of at least three different batches of each micro-
sphere formulation.
In  a  previous study [25] it  was demonstrated that smaller
sizes are obtained with 95/5 (%) of aqueous/organic phase. To
overcome the drawback of polydisperse population, the addition
of different stabilizers, on  formulations was  evaluated. One key
parameter to obtain small particles with a low PDl is  the type
of  surfactant/stabilizer used. A wide range of synthetic and nat-
ural molecules with varying properties has been proposed to
prepare particles. Nevertheless, for parenteral and topical appli-
cation nonionic surfactants, such as  tween 80,  pluronic F68 and
PVA, are  generally used [26].  However, PVA have a surfactant
character but its  stabilizing effect is exerted not through bound-
ary surface adsorption but by  increasing the viscosity of  water
[27–29].
Firstly, the efficiency of microspheres formation was  monitored
with the Lowry assay [22]. The addition of stabilizer for the pro-
duction of protein devices did not affect the yield of  microspheres
formation (≈100%). The effect of  stabilizers on  microspheres size
was then evaluated. In this experiment, PVA was the first adopted
stabilizer and BSA microspheres of different sizes were successfully
prepared controlling PVA amount (Table 1).
Results show that when PVA quantity is  increased, the size of
proteinaceous microspheres becomes much smaller. From Table 1,
it is possible to  verify that not only the size  of BSA microspheres
gets  effectively smaller, within a certain range, with the increasing
of  PVA amount, but also the particle size distribution, determined
as PDl, becomes narrower. There are two  main explanations for
these observations. Firstly, the tiny particles make wavy move-
ment and collide each other in an  emulsion leading to particles
aggregation. The polymerization degree of PVA used in  the exper-
iment can change the viscosity of  an aqueous solution decreasing
the wavy movement speed and the collision of  the tiny particles.
Secondly, the adsorption of PVA on  the surface of proteinaceous
microspheres can lower the surface energy and further agglomer-
ation of  proteinaceous microspheres [28,30]. The optimization of
stabilizer amount was  achieved at 8%, as higher percentages of PVA
did not present significant change in microspheres size and PDl.
Besides PVA, others macromolecular stabilizers have been
tested, namely, pluronic F68 and tween 80. The same behavior
was observed when different amounts of pluronic F68  and tween
80 were added to the formulation (data not shown). In Table 2
it is compared the effect of  the three stabilizers used on  the
Z-average, PDl and zeta-potential values of  the particles. PVA pre-
sented an high  ability to  reduce the particle sizes and, at the same
Table 2
Effect of  different stabilizers, PVA (8%), pluronic F68 (8%) and tween 80 (8%), on
Z-average  (nm), PDI and zeta-potential (mV) values of  BSA microspheres.
Stabilizers (8%) Z-Average (nm) PDl Zeta-potential (mV)
PVA 247.9 ± 5.9 0.060 ± 0.04 −3.9 ±  0.1
Pluronic F68 392.1 ± 60.1 0.29 ± 0.05 −2.9 ±  0.4
Tween 80 386.3 ± 17.1 0.28 ± 0.06 −3.5 ±  0.1
Values reported are the mean  ± SD of at least three different batches of each micro-
sphere formulation.
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time, decrease the PDl,  promoting a monomodal distribution of
BSA microspheres. Therefore, it  was used as standard 8%  of PVA
for all subsequent preparations. Apart from size determination,
zeta-potential was also evaluated to obtain an indication of micro-
spheres surface potential. The surface potential of the particles
cannot be  measured directly, the zeta-potential (electrical potential
at the surface of hydrodynamic shear around the colloidal particle)
is usually determined as a  characteristic parameter for the parti-
cle charge [31,32].  The  BSA microspheres possess a  zeta-potential
around −15  mV,  suggesting the presence of negative charge on the
microspheres surfaces (Table 2). Nevertheless, the zeta-potential of
the particles decreased significantly in  the presence of stabilizers
(Tables 1 and 2).
A survey of  the literature reveals that the measurement of zeta-
potential allows predict about the stability for colloidal dispersion
[33–35].  In  general, particle aggregation of charged particles (high
zeta-potential) is  less likely to occur, due to electric repulsion. How-
ever, this rule cannot be strictly applied to the systems containing
steric stabilizers, because the adsorption of the steric stabilizers
will decrease the zeta-potential, due to the shift in the shear plane
of the particle [36].
HSA was also tested in this work and the results obtained sub-
stantiate that HSA  contributed to a  small increase on  the Z-average
value (≈300 nm of  Z-average and 0.070 of  PDl), when compared
with BSA. In spite of the 80% of homology, present on  the pri-
mary structures of  the two proteins, the replacement of  some
hydrophobic amino acids by others (e.g. HSA has a single Trypto-
phan amino acid while BSA holds two  Tryptophan’s in  its  sequence
[37]), can explain this difference on  the size obtained, once  that, the
properties of  each amino acid demonstrated to be essential in the
physico-chemical parameters of  microspheres [25,38].  Conversely,
the zeta-potential of  microspheres prepared with 8%  of PVA and
BSA or HSA is  very similar (≈−4 mV).
3.2. Piroxicam entrapment
The entrapment efficiency of piroxicam into  BSA  or HSA
microspheres was assessed spectrophotometrically. Entrapment
efficiency refers to the ratio of  quantity entrapped/adsorbed drug
in relation to  the total (theoretical) amount of drug used for micro-
spheres production. Fig. 1  shows that PVA proved to  be successful
in enhancing drug incorporation efficiency in both types of pro-
teinaceous devices prepared. This can be attributed to the fact that
Fig. 1. Effect of PVA (8%) on the entrapment efficiency of  piroxicam (initial concen-
tration of  3 mM)  into BSA (5 g L−1) or HSA (5 g L−1) microspheres. Values express the
mean results ± SD  values of three different batches.
the presence of PVA decreases the size of particles leading to an
enhancing of the surface area, and as  a consequence more piroxi-
cam molecules are entrapped into proteinaceous microspheres.
Piroxicam entrapment efficiency is an  important factor, once
that the release rate  is usually dependent on drug concentration
gradient [39].  Furthermore, higher levels of drug incorporation lead
to  a wider  concentration gap between the polymeric/protein micro-
spheres and the release medium and can  cause a higher diffusion
rate. As previously demonstrated, the PVA  addition  led to a submi-
cron size and a relatively narrow particle size distribution. The drug
incorporation in microspheres resulted in a slightly bigger particles
with similar PDl values  (Fig. 2). The zeta-potential results (Fig. 3)
evidence that the presence of piroxicam did not affect significantly
the surface charge of proteinaceous microspheres.
3.3. Stability studies
Since those colloidal particles can suffer destabilization over
time [40],  particularly when stored in an  aqueous dispersion, par-
ticle size was monitored for two months after preparation in
order to evaluate their physical stability. The zeta-potential was
also determined, since this parameter can change over time, due
to degradation of  components of the colloidal particles [41]. In
an  electrostatically stabilized dispersion, charges generated on
Fig. 2. Z-Average (nm) and PDl of different formulations, prepared with BSA (5  g L−1) or HSA (5 g L−1), piroxicam (3 mM), with or without PVA (8%). Values reported are the
mean  ± SD of at  least three different batches of each microsphere formulation.
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Fig. 3. Zeta ()-potential (mV) of different formulations prepared with BSA
(5 g L−1)  or HSA (5 g L−1), piroxicam (3  mM),  with or without PVA (8%). Values
reported are the mean ± SD  of at least three different batches of  each microsphere
formulation.
the surface of  particles prevent or control agglomeration. Steric
stabilization takes place when large molecules adsorb onto the
surface of  particles, thus introducing physical barriers between
them [33].  A combination of electrostatic and steric mecha-
nisms produces electrosteric stabilization preventing microspheres
agglomeration.
Fig. 4  demonstrates that the presence of  PVA increases micro-
spheres’ stability, as the size and zeta-potential measurements
were roughly stable over time. Conversely, the entrapment of
piroxicam without PVA leads to an increase on Z-average values
and decrease zeta-potential values (≈0 mV), after one week of stor-
age. Furthermore, the stabilization of microemulsion with PVA is
attributed to the adsorbed chain molecules of PVA on the surface,
which have ceaseless thermal motion, resulting in  dynamically
rough surface preventing coalescence by  repulsive entropic force.
3.4. Morphology
STEM photographs, in  Fig. 5, illustrate that the obtained BSA
microspheres are clearly spherical homogeneous particles with
smooth surfaces. It was possible to  verify that the use of stabilizers
(PVA) promoted some restrictions on visualization of  microspheres,
due to their surface tension. The morphology of HSA microspheres
was  also evaluated and presents a  similarly spherical shape. This
morphology would offer the highest potential for controlled release
and protection of  incorporated drugs, as they provide minimum
contact with the aqueous environment, as well as  the longest diffu-
sion pathways. Comparing particles with any other shape, spherical
particles also require the smallest amount of surface-active agent
for stabilization, because of their small  specific surface area [23].
These results are also in  agreement with PCS results, once that the
particle size distribution was  very similar.
3.5. In vitro release profile
The two developed systems in this study aimed to be used
as carriers of an  anti-inflammatory molecule are: BSA-piroxicam
microspheres and HSA-piroxicam microspheres. One important
and desired property is biodegradation when designing drug
delivery systems. Biodegradable polymers are able to release the
entrapped drug as their degradation take places. Thus, by control-
ling the degradation rate of polymeric materials the drug release
can be identically monitored. For particulate drug delivery systems
the  enzymatic degradation is  a crucial parameter for the release of
an embedded drug. However, it  should be noted that  in vitro release
profile obtained might not be quantitatively predictive of the in vivo
behavior. Nevertheless, in vitro release studies allowed for screen-
ing and rank-ordering various formulations by the rates of drug
release and provide a  basis for in vivo  studies [42].  The release pro-
file  of  BSA or HSA-based particles, prepared with 5 g L−1 of protein,
8% of  PVA and with 3 mM  of  piroxicam, in  the presence of pro-
tease enzyme are presented in Fig. 6.  The release can  be divided
into two phases: an  initial burst in the first  hours and a continuous
release over the remaining time. The burst release of piroxicam
is associated with those piroxicam molecules dispersing close to
microspheres surface, which diffuse out in the initial incubation
time. According with the literature piroxicam revealed a  higher par-
tition capacity in  lipid bilayer and consequently present an  higher
Fig. 4. Z-Average (nm) and zeta ()-potential (mV) over  a timeline of two  months for different formulations prepared with BSA (5 g  L−1) or  HSA (5 g  L−1),  piroxicam (3 mM),
with  or without PVA (8%).  Values reported are the mean ±  SD  of at least three different batches of each microsphere formulation.
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Fig. 5. STEM images (×50,000 magnification) of protein microspheres: (a) BSA (5 g L−1) + piroxicam (3  mM);  (b) BSA (5 g L−1) +  PVA (8%) + piroxicam (3  mM); (c) HSA
(5  g L−1) + piroxicam (3 mM); (d) HSA (5 g L−1) + PVA (8%) + piroxicam (3  mM).
Kp value [43].  Additionally, location studies in liposomes showed
that piroxicam can be positioned with their hydrophilic part ori-
ented toward the polar part of membrane and their hydrophobic
segment in  the upper part of the lipophilic tails [43].  Thus, the
piroxicam, which is sparingly soluble in water, must be aligned
between the albumin molecules, in the protein layer contribut-
ing also for the initial burst release. It  was possible to verify that
BSA particles display a faster release of piroxicam, compared with
the release obtained with HSA microspheres. This result can be
attributed to the fact that  smaller particles have a  larger surface
area, therefore, most of the associated drug would be at or near
the particle surface leading to a  fast drug release. On the other
hand, the observed higher sizes of  HSA particles, can explain the
longer sustained release compared to  smaller particles. Different
concentrations of protease (0.073, 0.50 and 3.0 U mL−1) were used
for piroxicam release trigger on protein devices and the results of
Fig. 6 evidence that the higher concentration lead to the most rapid
diffuse out of drug.
A number of mathematical models have been proposed to
describe the mechanisms of  drug release from polymeric devices.
The Higuchi [44], Korsmeyer [45]  and Peppas [46,47] equations
are the most widely used to date and are  mainly based on the
Fickian diffusion equation. In order to analyze the release mech-
anism of piroxicam from the proteinaceous microspheres and the
effect of the protease concentrations over the release behavior, the
obtained data was processed using the empirical expression pro-
posed by Ritger–Peppas [46]. For a sphere, a Fickian diffusion of
first-order is observed when  n has the limiting value of 0.43; if
n = 0.85 occurs Case II transport (polymer relaxation/degradation),
leading to zero-order release. Finally, when n  lies between 0.43 and
0.85, Anomalous transport is observed coupling Fickian diffusion
and polymer degradation [46,47].
In  HSA microspheres (Table 3), the drug transport mecha-
nism obtained for all experimental conditions was Non-Fickian
diffusion or Anomalous (indication of the superposition of  both
extreme phenomena: drug diffusion and macromolecular chain
relaxation/degradation). This result indicates that neither absolute
Fickian diffusion (as result of pure drug diffusion) nor Case II-zero
order (because of  polymer chain relaxation/degradation) was  the
predominant mechanism in this case. Therefore, it can be concluded
that the protease concentration does not significantly influences
the drug transport mechanism, affecting solely the diffusion coeffi-
cient value. In Table 3 is possible to observe that BSA microspheres
in  the presence of higher protease concentrations present a higher
n value indicating the Case II-zero order nature, which means
that the piroxicam release is mainly due to the macromolecular
chain relaxation indicating the degradation of BSA microspheres.
The proteins chemical nature reveal a significant influence in  the
drug transport mechanism (Anomalous and Case II-zero order
nature), when higher enzyme concentrations are used,  affecting
the diffusion coefficient value. Moreover, correlation coefficient
“R2” is above the permissible range, that is,  0.95, further sup-
porting the validity of the results. Therefore, these proteinaceous
microspheres evidence their potential, for example, in topical
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Fig. 6. In vitro release profile of  piroxicam from BSA (a) and  HSA (b) microspheres
incubated with different concentrations of protease  (0.073, 0.50 and  3.0  U mL−1) and
with PBS buffer solution (control). Each point represents the mean ± SD values from
three different batches. The inset values show the  release profile over the  first  24 h.
applications in  the treatment of diseases where anti-inflammatory
drugs are needed, such as in chronic wounds [15,48].  Additionally,
the concentration of  piroxicam that was released after 5 min
(approximately 99 mM or 33 mg mL−1for  PBS and in presence of  3 U
of protease) and 24 h (approximately 367 mM or 120 mg mL−1and
1780 mM or 590 mg mL−1for PBS and in presence of 3 U  of  protease,
Table 3
Piroxicam release kinetic data obtained from fitting experimental release data to
Ritger–Peppas Equation (4),  where “n” is the  diffusion exponent and R2 is the cor-
relation coefficient.
Protease (U mL−1)  BSA  HSA
n  R2 n  R2
0.073 0.568 0.987 0.529 0.988
0.50 0.699 0.994 0.526 0.996
3.0  0.859 0.987 0.544 0.993
respectively), can  be enough to  obtain a therapeutical effect. In
fact, a  study present in  literature [50] shows that the concentration
of  piroxicam is in levels in  the order of 0.3–4.6 mg  mL−1 of  synovial
fluid, and in plasma the concentrations ranged between 0.5 and
8.3 mg mL−1.
3.6. Cytotoxicity evaluation
The biocompatibility of  the piroxicam entrapped on  proteina-
ceous devices was assessed in  fibroblast cultures. A preliminary
screening was made using murine embryonic fibroblasts cells
(MEFs), as  a measure of global cytotoxicity. In this study, a wide
range of  protein concentrations (from 75 to 5000 mg L−1) used for
inhibition assays was  evaluated and no toxicity was  observed for
the range concentrations of 75–300 mg  L−1.  The results obtained
with  MEFs were then confirmed with human skin fibroblasts, test-
ing the range protein concentrations (75–300 mg L−1) that  did not
induced any damage to MEFs cells.
The  effect of all tested conditions on  BJ5ta was evaluated after
24, 48 and 72 h  of culture, in order to  establish the effect of
drug entrapped in proteinaceous microspheres (BSA and HSA)
on exposed BJ5ta (Figs. 7 and 8). Results indicate that neither
protein  solutions (BSA and HSA), PVA solution (PVA Sol.) nor  veg-
etable oil induce any toxicity for the investigated culture times
(P >  0.05). However, it  is clear that the effect  of  piroxicam, in a
concentration of  0.5 mM,  on human fibroblasts cells  is statisti-
cally different when compared to  control cells (***P < 0.001) and
with the other tested samples (•••P  < 0.001). In Fig. 7 it  is possible
to verify that after 72 h  of  exposure to 300 mg L−1 of BSA micro-
spheres containing piroxicam, the viability of  BJ5ta decreased,
suggesting moderate cytotoxicity effects when compared with cells
control (**P < 0.01). Comparisons of  different concentrations of BSA
microspheres, containing piroxicam, with the other tested samples
were  also performed and statistically significant differences were
Fig. 7. BJ5ta cell viability at 24,  48 and  72 h of culture with different solutions and different concentrations of  BSA microspheres containing piroxicam (75, 150 and 300 mg  L−1).
Values for tested samples are presented in relation to the control (cells cultured with culture medium scored 100% of  viability). Statistically significant differences are
indicated. *,  significantly different from cells control; •,  significantly different from other tested conditions; +, significantly different from BSA Sol.; #, significantly different
from  Vegetable oil; d,  significantly different from 75, 150 and 300 mg  L−1 of  BSA microspheres. Results show the  mean values of  three replicates from two  experiments carried
out  independently.
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Fig. 8. BJ5ta cell viability at 24, 48  and 72 h of culture with different solutions and  different concentrations of HSA microspheres containing piroxicam (75, 150 and 300 mg L−1).
Values  for  tested samples are presented in  relation to  the  control (cells cultured with culture medium scored 100% of  viability). Statistically significant differences are
indicated.  *,  Significantly different from cells control; •, significantly different from other tested conditions; +,  significantly different from HSA Sol.; #, significantly different
from  Vegetable oil; d,  significantly different from 75,  150 and  300 mg L−1 of HSA microspheres. Results show the  mean values of  three replicates from two  experiments
carried  out independently.
obtained for the 300  mg  L−1 concentration, after 72 h (+ symbol:
BSA  Sol. vs. 300 mg  L−1 BSA; # symbol: Vegetable oil vs 300 mg L−1
BSA; d symbol: 150 and 75 mg L−1 BSA vs 300 mg L−1 BSA, P < 0.05).
In Fig. 8,  similar data is displayed for the viability of BJ5ta cells
in contact with HSA microspheres, containing piroxicam, which
further provides the evidence of cytotoxic effects after 72  h, when
300 mg L−1 of HSA microspheres concentration is used (+ symbol:
BSA Sol. vs 300 mg L−1 BSA; #  symbol: Vegetable oil vs 300 mg L−1
BSA; d symbol: 150 and 75  mg  L−1 BSA vs  300  mg L−1 BSA, P  < 0.05
and **  symbol: Cells vs 300  mg  L−1 BSA P  <  0.01). Statistically, it is
possible to observe that the range  concentrations of 75–150 mg  L−1
of  proteinaceous microspheres containing piroxicam, did not sig-
nificantly affect the  viability of human skin fibroblasts cells for a
period of 72 h, indicating that microspheres can be safely applied
at these concentrations.
4. Conclusion
The present study demonstrates the ability of proteinaceous
microspheres to  entrap the anti-inflammatory drug piroxicam.
BSA and HSA microspheres were produced with predictable and
reproducible size by  a sonochemical method. Furthermore, the
incorporation of PVA into the prepared formulations resulted in
improved characteristics, including smaller size, lower size dis-
tribution, higher stability and higher entrapment efficiency of
piroxicam. The kinetics of  piroxicam entrapped in  BSA or HSA
microspheres release mechanism was shown to be dependent on
the protein and on protease concentration. The fast release is
achieved when the drug is entrapped into BSA  microspheres and
in the presence of  high protease concentration (3.0 U mL−1). How-
ever, if it is necessary a slower release the piroxicam should be
incorporated in HSA microspheres. This fact, along with the cyto-
compatibility observed with human skin fibroblasts, indicates that
these proteins may  potentially be used as potential bioactive carri-
ers for treatment of inflammatory diseases. In this sense, such drug
carriers with a specific size range can  be invaluable therapeutic
tools for  other pathologies where the NSAIDs can be  useful, such as
cancer, Alzheimer and artherosclerosis [1,51–53].
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